Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 159 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety and Recovery Therapy Clear all
Completed Phase 1 Interventional Results available

High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma

NCT01313936
View directory record Official record
Conditions
Neuroblastoma
Interventions
Metaiodobenzylguanidine (MIBG)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year to 30 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)

NCT00627393
View directory record Official record
Conditions
Neutropenia, Infection
Interventions
Standard antimicrobial therapy, Granulocyte transfusions, G-CSF/dexamethasone, Apheresis machine
Drug · Biological · Device
Lead sponsor
Carelon Research
Other
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
13
States / cities
Iowa City, Iowa • Baltimore, Maryland • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 8, 2026, 5:37 AM EDT
Not listed Not applicable Interventional

High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease

NCT00247143
View directory record Official record
Conditions
HIV, AIDS
Interventions
Kaletra (drug)
Drug
Lead sponsor
Lampiris, Harry W., M.D.
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2006 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Not applicable Interventional Results available

Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression

NCT03191058
View directory record Official record
Conditions
Depression, Unipolar Depression, Treatment Resistant Depression
Interventions
Magnetic Seizure Therapy, Electroconvulsive Therapy
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 8, 2026, 5:37 AM EDT
Not yet recruiting Phase 3 Interventional

An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service

NCT07296770
View directory record Official record
Conditions
Postsurgical Pain Management, Postsurgical Pain, Chronic, Opioid Use After Surgery
Interventions
TPS-Select, Pharmacologic Pain Management, Interventional Pain Procedures, Psychological Management and Pain Education, Physical Therapy
Device · Drug · Procedure + 1 more
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 8, 2026, 5:37 AM EDT
Recruiting Phase 1 Interventional

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

NCT07283094
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Decitabine, Venetoclax, FHD-286
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 8, 2026, 5:37 AM EDT
Recruiting Not applicable Interventional

Project STRONGER: Stepped Care for Opioid Use Disorder Treatment Engagement and Recovery

NCT07115030
View directory record Official record
Conditions
Opioid Use Disorder, Intimate Partner Violence (IPV), Post Traumatic Stress Disorder PTSD
Interventions
PCT+2HOPE
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Bridgeport, Connecticut • Enfield, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 8, 2026, 5:37 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

NCT04557059
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radiotherapy, LHRHa, Apalutamide
Radiation · Drug
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
18 Years and older · Male only
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
13
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The PREFORM Study: Rotational Fractional Resection for Submental Contouring

NCT03966924
View directory record Official record
Conditions
Skin Laxity, Lipodystrophy
Interventions
Rotational fractional resection (1.5mm Diameter Device)
Device
Lead sponsor
Recros Medica, Inc.
Industry
Eligibility
30 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Not applicable Interventional Results available

Primary Care Brief Mindfulness Training for Veterans With PTSD

NCT03352011
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
Primary Care Brief Mindfulness Training, PTSD Psychoeducational Class
Behavioral
Lead sponsor
Syracuse VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 8, 2026, 5:37 AM EDT
Withdrawn Not applicable Interventional

Study to Assess Safety & Effects of Autologous ADSCs During Recovery Phase of ST-Elevation MI Effects of Autologous ADSC Implantation During Subacute Recovery Phase of ST-Elevation Myocardial Infarction

NCT03272191
View directory record Official record
Conditions
Subacute Myocardial Infarction
Interventions
Liposuction and stem cell implantation
Procedure
Lead sponsor
Ageless Regenerative Institute
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19

NCT04527471
View directory record Official record
Conditions
Coronavirus Infection, Covid-19, SARS-CoV-2
Interventions
Ensifentrine Dose 1, Placebo pMDI
Drug
Lead sponsor
Verona Pharma Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 8, 2026, 5:37 AM EDT
Recruiting Phase 2 Interventional

A Study of Brenipatide in Participants With Opioid Use Disorder

NCT07420283
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Brenipatide, Placebo, Buprenorphine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 8, 2026, 5:37 AM EDT
Recruiting Not applicable Interventional

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

NCT07010757
View directory record Official record
Conditions
PTSD, Obesity
Interventions
HARPP, control arm for HARPP trial
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes

NCT00007904
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, adjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
3
States / cities
Cleveland, Ohio • Mentor, Ohio • Orange, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Oct 8, 2026, 5:37 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Phase 3 Interventional Results available

Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)

NCT04546581
View directory record Official record
Conditions
COVID, COVID-19, SARS-CoV-2, SARS (Severe Acute Respiratory Syndrome)
Interventions
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo, Remdesivir
Biological · Other · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Colorado Springs, Colorado • Lakewood, Colorado • Westminster, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Not applicable Interventional Results available

Feasibility of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Shoulder/Foot Surgery

NCT06818708
View directory record Official record
Conditions
Rotator Cuff Injuries, Shoulder Disease, Hallux Valgus, Ankle Arthropathy
Interventions
Experimental Treatment
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 8, 2026, 5:37 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Opioids and Police Safety Study

NCT05008523
View directory record Official record
Conditions
Opioid Overdose
Interventions
Opioids and Police Safety Occupational Risk Reduction Training (OPS), Opioids and Police Safety Occupational Risk Reduction Training (COVID)
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

Trial of Ropinirole in Motor Recovery After Stroke

NCT00221390
View directory record Official record
Conditions
Cerebrovascular Accident, Hemiparesis
Interventions
Ropinirole (+ physical therapy), (vs.) Placebo + physical therapy
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

NCT04196491
View directory record Official record
Conditions
Multiple Myeloma
Interventions
bb2121, Fludarabine, Cyclophosphamide, Lenalidomide
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 8, 2026, 5:37 AM EDT
Completed Phase 1 Interventional

CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment

NCT00482521
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
CC-4047
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2012 · Synced Oct 8, 2026, 5:37 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

NCT05053880
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme(GBM)
Interventions
ACT001, ACT001 + Pembrolizumab
Drug
Lead sponsor
Accendatech USA Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 8, 2026, 5:37 AM EDT
Active, not recruiting Phase 2 Interventional

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

NCT04835129
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab (for run-in portion), Isatuximab (for expansion), Pomalidomide, Elotuzumab, Dexamethasone
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 8, 2026, 5:37 AM EDT